L 345 | CAS#121809-82-3 | bioactive chemical

MedKoo Cat#: 559184 | Name: L 345

Description:

WARNING: This product is for research use only, not for human or veterinary use.

L 345 is a bioactive chemical.

Chemical Structure

L 345

CAS#121809-82-3

Theoretical Analysis

MedKoo Cat#: 559184

Name: L 345

CAS#: 121809-82-3

Chemical Formula: C17H15Cl3N2O4

Exact Mass: 416.0097

Molecular Weight: 417.66

Elemental Analysis: C, 48.89; H, 3.62; Cl, 25.46; N, 6.71; O, 15.32

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

L 345; L-345; L345;

IUPAC/Chemical Name

2-methyl-2-(4-(3-(3,4,5-trichlorophenyl)ureido)phenoxy)propanoic acid

InChi Key

RETXRBKBFDJBQS-UHFFFAOYSA-N

InChi Code

InChI=1S/C17H15Cl3N2O4/c1-17(2,15(23)24)26-11-5-3-9(4-6-11)21-16(25)22-10-7-12(18)14(20)13(19)8-10/h3-8H,1-2H3,(H,23,24)(H2,21,22,25)

SMILES Code

CC(OC1=CC=C(NC(NC2=CC(Cl)=C(Cl)C(Cl)=C2)=O)C=C1)(C)C(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 417.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Horjen AW, Seljeflot I, Berge T, Smith P, Arnesen H, Tveit A. Effect of sinus rhythm restoration on markers of thrombin generation in atrial fibrillation. Thromb J. 2017 Dec 28;15:30. doi: 10.1186/s12959-017-0153-1. eCollection 2017. PubMed PMID: 29299030; PubMed Central PMCID: PMC5745972. 2: Riddle MC. Diabetes: Controlling glucose levels in elderly people--benefits versus risks. Nat Rev Endocrinol. 2015 May;11(5):257-8. doi: 10.1038/nrendo.2015.23. Epub 2015 Feb 24. PubMed PMID: 25707784. 3: Bi XY, Zhao JJ, Yan T, Li C, Zhou HT, Huang Z, Zhao H, Cai JQ. [Peri-operative treatment for hepatocellular carcinoma patients complied with cirrhosis and hypersplenism]. Zhonghua Wai Ke Za Zhi. 2010 Oct 15;48(20):1539-41. Chinese. PubMed PMID: 21176666. 4: Riddle MC. Therapy: What evidence should guide the use of thiazolidinediones? Nat Rev Endocrinol. 2010 Nov;6(11):600-2. doi: 10.1038/nrendo.2010.156. PubMed PMID: 20962864. 5: Riddle MC. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation. 2010 Aug 24;122(8):844-6. doi: 10.1161/CIRCULATIONAHA.110.960138. PubMed PMID: 20733112; PubMed Central PMCID: PMC2980502. 6: Riddle MC. Combined therapy with insulin plus oral agents: is there any advantage? An argument in favor. Diabetes Care. 2008 Feb;31 Suppl 2:S125-30. doi: 10.2337/dc08-s231. PubMed PMID: 18227472. 7: Riddle MC. Starting and advancing insulin for type 2 diabetes: algorithms and individualized methods are both necessary. J Clin Endocrinol Metab. 2008 Feb;93(2):372-4. Epub 2007 Dec 11. PubMed PMID: 18073293. 8: Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care. 1998 Jul;21(7):1052-7. PubMed PMID: 9653594. 9: Kister J, Griffon N, Henthorn JS, Marden MC, Poyart C, Papassotiriou I, Promé D, Galactéros F, Davies SC, Wajcman H. Alteration of an intersubunit contact in hemoglobin variants: comparative study of modifications at position alpha 126 Asp (H9). C R Acad Sci III. 1997 Nov;320(11):849-55. PubMed PMID: 9499936. 10: Dumoulin A, Kiger L, Jiang R, Baudin V, Vasseur C, Sligar SG, Marden MC, Pagnier J, Poyart C. Loss of allosteric behaviour in recombinant hemoglobin alpha 2 beta 2(92)(F8) His-->Ala: restoration upon addition of strong effectors. FEBS Lett. 1995 Oct 23;374(1):39-42. PubMed PMID: 7589508. 11: Yamamoto J, Ohyanagi M, Morita M, Iwasaki T. Beta-adrenoceptor-G protein-adenylate cyclase complex in rat hearts with ischemic heart failure produced by coronary artery ligation. J Mol Cell Cardiol. 1994 May;26(5):617-26. PubMed PMID: 8072016. 12: Lalezari I, Lalezari P, Poyart C, Marden M, Kister J, Bohn B, Fermi G, Perutz MF. New effectors of human hemoglobin: structure and function. Biochemistry. 1990 Feb 13;29(6):1515-23. PubMed PMID: 2334712. 13: Langner NR, Hasselback PD, Dunkley GC, Corber SJ. Attitudes and practices of primary care physicians in the management of elevated serum cholesterol levels. CMAJ. 1989 Jul 1;141(1):33-8. Erratum in: Can Med Assoc J 1989 Aug 15;141(4):278. PubMed PMID: 2731100; PubMed Central PMCID: PMC1269270.